by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide, yet clinical trials remain unrepresentative of those most affected. Ethnic minoritized groups, socioeconomically deprived communities, adults over 75, and populations in low- and...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 10, October 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 26, 2026 Neuro-Dementia...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract BACKGROUND Individuals with Alzheimer’s disease (AD) dementia can be subgrouped based on cognitive performance at diagnosis. We compared neuropathology across cognitively defined AD subgroups in the Adult Changes in Thought study. METHODS Scores for...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract INTRODUCTION Dementia with Lewy bodies (DLB) is a common but underdiagnosed neurodegenerative disease associated with α-synuclein pathology. Clinically, DLB is characterized by early motor dysfunction and psychiatric symptoms, in contrast to early memory...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract Sleep disturbances are highly prevalent in older adults and are particularly common among individuals attending memory clinics for assessment of cognitive impairment. Emerging evidence links sleep disorders, including insomnia, obstructive sleep apnea,...
by Clinical Neuropsychologist Online | Sunday, October 25, 2026 | Dementia
Abstract INTRODUCTION 18F-MK6240 is a second-generation tau positron emission tomography (PET) tracer with high dynamic range able to detect early tau pathology in Alzheimer’s disease, however, its binding characteristics have not been evaluated in Down syndrome...
